Browse the evidence

Gastrointestinal side effects were more common with GI181771X than with placebo treatment.

Clinicians should monitor for gastrointestinal side effects in patients taking GI181771X.

Greater numbers of participants correlated with smaller differences in weight loss.

Larger studies may yield more conservative estimates of diet effectiveness.

The mean effect of individualized lifestyle interventions for weight reduction in people with SMI is statistically significant but clinically insignificant.

Practitioners should be aware that while interventions may show statistical benefits, the practical impact on weight may be limited.

Pioglitazone and GLP-1 receptor agonists are promising treatments for NAFLD that also benefit the vasculature.

Clinicians may consider these medications for managing NAFLD and associated cardiovascular risks.

Exercise-induced increases in GH and testosterone do not enhance strength and hypertrophy adaptations.

Practitioners should focus on intrinsic muscle mechanisms rather than hormonal changes for strength and hypertrophy.

Longitudinal data indicate that variability in TEF is not associated with changes in body weight.

TEF variability may not be a reliable predictor of weight management.

Insulin action has a familial component, with heritability estimates ranging from 0.38 to 0.61 depending on conditions.

Understanding insulin action's genetic basis can aid in diabetes prevention strategies.

Alterations in SNS effects on metabolism have been implicated in the development and maintenance of obesity.

Recognizing the role of SNS alterations can inform obesity treatment approaches.

The SNS is a potential therapeutic target in the treatment of obesity.

Targeting the SNS could lead to new obesity treatment strategies.

Glucose ingestion during exercise decreases the expression of genes involved in lipid metabolism.

Practitioners should consider that glucose ingestion during exercise may hinder fat metabolism.

Glucose ingestion during exercise blunts the increase in plasma free fatty acid levels.

Glucose intake during exercise may limit fat utilization by affecting FFA levels.

There was no significant effect of whey or soy alone on LBM change.

Neither whey nor soy protein alone is effective for increasing LBM.

Long-term adherence to a gluten-free diet was adequate in over 75% of respondents.

Practitioners can expect that a significant majority of adults with coeliac disease adhere to a gluten-free diet long-term.

Exercise training improved insulin-stimulated glucose transport and increased rates of fatty acid oxidation in skeletal muscle.

Incorporating exercise training can significantly enhance glucose metabolism and fat oxidation in individuals with insulin resistance.

Both exercise training and rosiglitazone decreased liver triacylglycerol content.

Both exercise and rosiglitazone may be beneficial for reducing liver fat content.

Carbohydrate ingestion during exercise does not result in a significant sparing of muscle glycogen or an improvement in cycling performance during 2 hours of exercise when initial glycogen levels are elevated.

Practitioners should note that carbohydrate drinks may not enhance performance or glycogen preservation in well-trained cyclists with high initial glycogen levels.

No significant differences were observed between trials in blood lactate, serum glycerol, respiratory exchange ratio, or the subjects' perception of effort.

The type of carbohydrate drink consumed does not significantly affect other metabolic parameters or perceived exertion during cycling.

Beetroot juice supplementation did not enhance cycling time trial performance when used alone or in combination with caffeine.

Beetroot juice may not be effective for enhancing cycling performance in competitive settings.

Caffeine and beetroot juice combined did not provide an additive effect on cycling time trial performance.

Combining caffeine with beetroot juice may not yield additional performance benefits for cyclists.

The risk of cardiovascular events or death increases progressively from normoglycaemic to newly diagnosed diabetics.

Interventions aimed at improving glucose metabolism may reduce cardiovascular risk across different populations.

The article discusses the role of skeletal muscle in health and disease.

Understanding skeletal muscle's role can inform approaches to health and disease management.

SCD1 is a key enzyme that regulates energy homeostasis and various physiological processes.

Understanding SCD1's role can help in targeting metabolic diseases.

Aberrant activation of SCD1 contributes to obesity, non-alcoholic fatty liver, diabetes, and cancer.

Targeting SCD1 may help in managing these metabolic diseases.

Resting metabolic rate (RMR), adjusted for fat-free mass, fat mass, and sex, was lower in both older groups (60-74 years and >or=90 years) compared to the young group (20-34 years) (p<or=.0001).

Older adults may have a lower metabolic rate, which could influence weight management strategies.